Literature DB >> 9427314

Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance.

S Luo1, J Luo, A H Meier, A H Cincotta.   

Abstract

Dopaminergic neuron neurotoxin (6-hydroxydopamine; 6-OHDA) administration directed to the hypothalamic area of the mammalian pacemaker, the suprachiasmatic nuclei (SCN), was carried out on lean, glucose tolerant hamsters to investigate the possibility that dopaminergic input to the vicinity of the SCN is necessary to maintain this metabolic condition. Glucose tolerance tests (GTT, 3 g glucose/kg) were performed 4 days prior to and 16 days after neurotoxin lesioning. 6-OHDA administration to the area of the SCN resulted in both a significant 58% increase in daily food consumption by the 16th day post-lesioning, and a 85% increase in weight gain 4 and 8 weeks after lesioning relative to controls. Such treatment also significantly increased the total areas under the GTT glucose and insulin curves by 48% and 400% respectively, compared with controls. These findings indicate that body weight gain, glucose intolerance and insulin resistance result from decreased dopaminergic input to the area of the SCN.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427314     DOI: 10.1097/00001756-199711100-00016

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

1.  Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model.

Authors:  Mary Courtney Moore; Marta S Smith; Larry L Swift; Anthony H Cincotta; Michael Ezrokhi; Nicholas Cominos; Yahong Zhang; Ben Farmer; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-05-27       Impact factor: 4.310

2.  Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.

Authors:  J Michael Gaziano; Anthony H Cincotta; Christopher M O'Connor; Michael Ezrokhi; Dean Rutty; Z J Ma; Richard E Scranton
Journal:  Diabetes Care       Date:  2010-03-23       Impact factor: 17.152

3.  Interaction between the obesity-risk gene FTO and the dopamine D2 receptor gene ANKK1/TaqIA on insulin sensitivity.

Authors:  Martin Heni; Stephanie Kullmann; Emma Ahlqvist; Robert Wagner; Fausto Machicao; Harald Staiger; Hans-Ulrich Häring; Peter Almgren; Leif C Groop; Dana M Small; Andreas Fritsche; Hubert Preissl
Journal:  Diabetologia       Date:  2016-09-06       Impact factor: 10.122

Review 4.  Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.

Authors:  Ralph A Defronzo
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

5.  Bromocriptine in type 2 diabetes mellitus.

Authors:  C Shivaprasad; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2011-07

6.  Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.

Authors:  Michael Ezrokhi; Shuqin Luo; Yelena Trubitsyna; Anthony H Cincotta
Journal:  Diabetol Metab Syndr       Date:  2014-09-25       Impact factor: 3.320

7.  Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.

Authors:  Bindu Chamarthi; J Michael Gaziano; Lawrence Blonde; Aaron Vinik; Richard E Scranton; Michael Ezrokhi; Dean Rutty; Anthony H Cincotta
Journal:  J Diabetes Res       Date:  2015-04-28       Impact factor: 4.011

8.  Rethinking energy in parkinsonian motor symptoms: a potential role for neural metabolic deficits.

Authors:  Shinichi Amano; Deborah Kegelmeyer; S Lee Hong
Journal:  Front Syst Neurosci       Date:  2015-01-06

9.  Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.

Authors:  Michael Ezrokhi; Yahong Zhang; Shuqin Luo; Anthony H Cincotta
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

10.  Premature ejaculation in type II diabetes mellitus patients: association with glycemic control.

Authors:  Ahmad Majzoub; Mohamed Arafa; Sami Al-Said; Zeinab Dabbous; Samar Aboulsoud; Kareim Khalafalla; Haitham Elbardisi
Journal:  Transl Androl Urol       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.